Gliminyle MP 1mg/500mg/15mg Tablet ER
Marketer
Erinyle Pharma
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Pioglitazone (15mg)
Overview Gliminyle MP 1mg/500mg/15mg Tablet ER
Glyburide/Metformin/Pioglitazone extended-release tablets (1mg/500mg/15mg) offer combined blood glucose management. This medication, used alongside diet and exercise, improves glycemic control in adults with type 2 diabetes. It enhances insulin effectiveness, reducing blood sugar. Dosage and frequency should strictly follow your physician's instructions. Take with food to prevent digestive discomfort. If a dose is missed, take it promptly unless the next dose is imminent; then, skip the missed dose and resume your normal schedule. Never double the dose. Overdosage risks hypoglycemia (low blood sugar). Concurrent use with other diabetes medications, alcohol, or skipped meals elevates hypoglycemia risk; regular blood sugar monitoring is vital. Common side effects may include nausea, diarrhea, abdominal pain, headache, bone fractures, and respiratory infections. Prior to initiating treatment, disclose any kidney, liver, or heart conditions to your doctor. Pregnant or lactating individuals require medical consultation before use. Kidney function tests will be conducted before treatment commences. Limit alcohol consumption to minimize potential side effects.
Uses of Gliminyle MP 1mg/500mg/15mg Tablet ER
Managing type 2 diabetes
Major Benefits of Gliminyle MP 1mg/500mg/15mg Tablet ER:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the entire tablet without chewing, crushing, or dividing it. Gliminyle MP 1mg/500mg/15mg Extended-Release Tablets should be administered with meals.
Common Side effects of Gliminyle MP 1mg/500mg/15mg Tablet ER:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Gliminyle MP 1mg/500mg/15mg Tablet ER:
Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Gliminyle MP 1mg/500mg/15mg Extended-Release tablets with food.
How Gliminyle MP 1mg/500mg/15mg Tablet ER works:
Gliminyle MP 1mg/500mg/15mg Extended-Release tablets combine glimepiride, metformin, and pioglitazone—three distinct antidiabetic agents—to optimize blood glucose management when monotherapy or dual therapy proves insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion, reducing blood glucose levels. Metformin, a biguanide, acts through multiple pathways: decreasing hepatic glucose production, slowing intestinal glucose absorption, and enhancing insulin responsiveness. Pioglitazone, a thiazolidinedione, further augments insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking Gliminyle MP 1mg/500mg/15mg Tablet ER is unsafe.
PregnancyCONSULT YOUR DOCTOR
The extended-release Gliminyle MP 1mg/500mg/15mg tablet might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Gliminyle MP tablets (1mg/500mg/15mg) are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyCAUTION
Patients with kidney impairment should use Gliminyle MP 1mg/500mg/15mg Extended-Release tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. Gliminyle MP 1mg/500mg/15mg Extended-Release tablets are contraindicated in individuals with severe kidney disease. Regular monitoring of renal function is recommended during treatment.
LiverCAUTION
Patients with liver impairment should exercise caution when using Gliminyle MP 1mg/500mg/15mg Extended-Release tablets. Dosage modification may be necessary. Physician consultation is advised. Gliminyle MP 1mg/500mg/15mg Extended-Release tablets are contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Gliminyle MP 1mg/500mg/15mg Tablet ER :
Should you forget a Gliminyle MP 1mg/500mg/15mg Extended-Release Tablet dose, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Gliminyle MP 1mg/500mg/15mg Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently